Carlos Ferrario to Treatment Outcome
This is a "connection" page, showing publications Carlos Ferrario has written about Treatment Outcome.
Connection Strength
0.340
-
Ferrario CM, Joyner J, Colby C, Exuzides A, Moore M, Simmons D, Bestermann W, Frech-Tamas F. The COSEHC™ Global Vascular Risk Management quality improvement program: first follow-up report. Vasc Health Risk Manag. 2013; 9:391-400.
Score: 0.070
-
Ferrario CM, Panjabi S, Buzinec P, Swindle JP. Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations. Ther Adv Cardiovasc Dis. 2013 Feb; 7(1):27-39.
Score: 0.067
-
Schindler C, Bramlage P, Kirch W, Ferrario CM. Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc Health Risk Manag. 2007; 3(1):125-37.
Score: 0.044
-
Smith RD, Yokoyama H, Averill DB, Cooke L, Brosnihan KB, Schiffrin EL, Ferrario CM. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. Am J Cardiovasc Drugs. 2006; 6(5):335-42.
Score: 0.041
-
Ferrario CM, Smith RD. Cost-effectiveness of impedance cardiography testing in uncontrolled hypertension. Am Heart Hosp J. 2006; 4(4):279-89.
Score: 0.041
-
Ferrario C, Abdelhamed AI, Moore M. AII antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan. Curr Med Res Opin. 2004 Mar; 20(3):279-93.
Score: 0.036
-
Ferrario CM, Smith RD, Brosnihan B, Chappell MC, Campese VM, Vesterqvist O, Liao WC, Ruddy MC, Grim CE. Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. Am J Hypertens. 2002 Jun; 15(6):557-64.
Score: 0.032
-
Pachori AS, Numan MT, Ferrario CM, Diz DM, Raizada MK, Katovich MJ. Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy. Hypertension. 2002 May; 39(5):969-75.
Score: 0.008